Revenue up 7.1% but PBT flat as cash conversion halved and leverage climbed...

What changed

Revenue rose 7.1% to NZ$6,582.5m and statutory EBITDA rose 4.8% to NZ$303.1m (underlying EBITDA NZ$313.2m, up 8.3%). PBT was effectively flat at NZ$192.0m (-0.3%), while NPAT edged up 3.0% to NZ$136.2m on a marginally lower effective tax rate (28.5% vs 28.6%). The mix stayed dominated by Healthcare (95.7% of revenue, segment result up 7.3% to NZ$273.6m); Animal Care revenue fell to NZ$286.2m from NZ$291.2m and its segment result slipped 7.5% to NZ$47.2m.

The more material moves were below the P&L:

• Operating cash flow fell 34.5% to NZ$105.5m, dragging OCF/EBITDA from 55.7% to 34.8%.
• Capex nearly doubled to NZ$64.3m (1.0% of revenue vs 0.6%), collapsing pre-lease free cash flow to NZ$41.2m from NZ$126.3m.
• Gross borrowings rose 37.1% to NZ$1,453.6m; net debt climbed to ~NZ$1,088.2m from ~NZ$837.5m, pushing net debt/EBITDA to 3.6x from 2.9x.
• Inventories rose 11.8% to NZ$1,334.3m despite only 7.1% revenue growth.
• Interim dividend was lifted 7.5% to NZ$0.57 per share.

What matters

Earnings growth has decelerated sharply. A year ago EBOS delivered 17.0% revenue growth and 29.8% NPAT growth on the HY23 comparable; this half it is 7.1% and 3.0%, with PBT actually flat. With tax essentially unchanged, PBT is the cleaner operating read and it is going sideways. Management flags roughly 10% normalised underlying EBITDA growth, but the gap between statutory (+4.8%) and underlying (+8.3%) EBITDA is not bridged in the extract.

Cash quality deteriorated materially. OCF/EBITDA roughly halved, and the combined effect of higher inventories and doubled capex means the interim dividend (payout at ~80.3% of NPAT) is running at about 265% of pre-lease free cash flow versus 79.7% a year ago. This half's dividend is being funded from the balance sheet, not from free cash.

Leverage moved in the wrong direction. Net debt/EBITDA of 3.6x is a material step-up from 2.9x, and sits alongside the elevated growth capex. That combination constrains optionality for further M&A without equity or a visible working-capital reversal in H2.

Expectations

No quantified FY24 targets, forward work or guidance were disclosed. Annualising HY24 revenue gives NZ$13.17b, about 7.6% above the FY23 anchor of NZ$12.24b. The FY23 shape was broadly even between halves on revenue and EBITDA (H1 took 50.2% and 50.8%) and slightly H1-weighted on NPAT (52.2%), so there is no obvious seasonal tailwind for the second half to recover the PBT shortfall. Recovering FY23's 25.1% NPAT growth trajectory is not supported by what the release shows; matching FY23 NPAT would require H2 NPAT of ~NZ$117.2m, modestly below the prior H2.

Quality of result

The revenue and underlying EBITDA beats are real but markedly slower than the prior comparable, and the underlying-to-statutory reconciliation is not provided in the extract. More of the NPAT growth than appears is being delivered below the operating line: PBT is flat, and NPAT growth is explained by a fractionally lower tax rate, not by operating leverage.

Working capital and capex are the bigger quality concerns. Inventories grew almost 12% against 7.1% revenue growth, and while receivable days actually improved slightly (42.2 vs 44.7), the inventory build plus a near-doubling of capex drained more than NZ$85m of pre-lease free cash flow versus last year. ROE was flat at 11.7% despite a larger balance sheet. Overall, the half looks meaningfully balance-sheet-assisted: higher borrowings and a larger cash outflow cycle are supporting both growth investment and the lifted dividend.

Unresolved

• What is the split between organic and acquisition-driven growth, and how much of the capex step-up is recurring run-rate versus one-off capacity investment?
• Why did Animal Care segment result fall 7.5% on only a 1.7% revenue decline, and is the margin compression cyclical or structural?
• What is the bridge from statutory EBITDA (+4.8%) to underlying EBITDA (+8.3%) and to the "approximately 10%" normalised figure cited in the release?
• Is the NZ$140.3m inventory build deliberate (new contract ramp, stockpiling) or a sell-through issue, and will it unwind in H2?
• With net debt/EBITDA at 3.6x, what covenant headroom and debt-maturity profile sit behind the gross borrowings of NZ$1.45b?

This briefing cannot assess management's forward outlook, covenant terms, or the mechanics of the underlying-to-statutory earnings reconciliation because none of those were disclosed in the supplied extracts.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.